Associate Director, Access Strategy and Marketing
Revolution Medicines
Summary
The Associate Director will lead the strategy, development, and execution of access marketing materials for the RevMed portfolio with a focus on pancreatic adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC).
Job description
The Opportunity
The Associate Director will lead the strategy, development, and execution of access marketing materials for the RevMed portfolio with a focus on pancreatic adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC).
This role will focus on developing the short to medium term non-clinical value proposition across payers, HCPs, organized customers (GPOs, IDNs, etc) and channel partners. The Associate Director will support post-launch monitoring and lead strategic and tactical planning for new launches. This role will tailor messaging to distinct customer segments and collaborate closely with Brand Marketing, National Account, Medical/HEOR, Regulatory, and Compliance partners. This role will require the ability to educate and influence internal stakeholders on Market Access strategy, key decisions, and implications.
Responsibilities
- Support the development and execution of access marketing strategies to align with brand and portfolio strategies.
- Develop value proposition messaging and materials for payers, PBMs, IDNs, GPOs, channel partners, and other managed care decisionmakers.
- Translate clinical, economic, and real-world evidence into compelling messages that communicate the portfolio’s value and address stakeholder evidence needs.
- Develop and execute a customer insights plan and partner with National Accounts and field teams to gather insights, refine messaging, and develop materials.
- Execute compliant marketing tactics for GPOs and organized providers across relevant channels.
- Coordinate launch readiness activities across Market Access teams.
- Lead pull-through and training for materials and market access initiatives.
- Manage day-to-day agency projects, timelines, deliverables, and assigned budgets.
- Work with Brand Marketing, Regulatory, and Compliance to align materials with brand goals and compliance requirements.
Required Skills, Experience and Education
- Bachelor’s degree required with 6+ years of experience in Marketing, Product Planning, and/or Managed Care.
- Experience in new product launches, including tactical execution.
- Strong understanding of the access landscape across all market access stakeholders.
- Excellent organizational skills and ability to prioritize and effectively deliver results within established timelines.
- Ability to represent Revolution Medicines well: strong interpersonal skills including verbal and written communication.
- Ability to travel up to 25%.
Preferred Skills
- 8+ years of experience in Marketing and/or Managed Care.
- Oral oncolytic product experience strongly preferred.
- Understanding of distribution models and patient support programs.
- Prior experience working with Compliance and Regulatory teams.
- Prior experience in customer-facing roles.
Requirements
- Bachelor’s degree required
- 6+ years of experience in Marketing, Product Planning, and/or Managed Care
- Experience in new product launches, including tactical execution
- Strong understanding of the access landscape across all market access stakeholders
- Excellent organizational skills and ability to prioritize and deliver results within established timelines
- Strong interpersonal skills including verbal and written communication
- Ability to travel up to 25%
Benefits
- Competitive cash compensation
- Robust equity awards
- Strong benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.